德国医生、药师与消费者药品不良反应报告信息完整性的比较分析
该研究基于2018–2021年EudraVigilance数据库中德国医生(n=69,976)、药师(n=42,396)和消费者(n=121,144)的个例报告,用vigiGrade评分评估完整性。医生报告平均完整性略高于消费者和药师(均数0.5 vs 0.4 vs 0.4),消费者报告在发病时间上更常可计算,但适应症填写少于医生。消费者报告完整性评分与医生、药师相当,凸显其价值。
要点
- 医生报告vigiGrade平均完整性略高于消费者和药师(0.5 vs 0.4 vs 0.4)。
- 消费者报告更常可计算ADR发病时间(OR 1.9 vs 医生;OR 1.7 vs 药师)。
- 药师和消费者报告适应症填写少于医生(OR均为0.5)。
核心结论
- 消费者ADR报告的完整性评分与医生和药师相当,凸显其价值。
- 不同报告者类型在特定信息完整性上存在差异,提示三者共同报告可能进一步提升完整性。
- 按报告者类型分层分析可能有助于特定科研目的。
研究设计与样本
- 分析2018–2021年EudraVigilance数据库中德国仅由医生(n=69,976)、药师(n=42,396)或消费者(n=121,144)提交的自发报告。
- 采用vigiGrade评分评估报告完整性,并用logistic回归计算OR及95%CI。
主要发现
- 研究期间医生和药师年报告数持续下降,消费者报告呈相反趋势。
- 药师和消费者报告中女性患者比例分别为64.4%和64.8%,高于医生报告的55.3%。
- 药师报告患者平均年龄58.7岁,高于医生(53.5岁)和消费者(52.6岁)。
- 消费者报告比医生报告(OR 1.9 [1.8-1.9])和药师报告(OR 1.7 [1.6-1.7])更常可计算ADR发病时间。
- 药师(OR 0.5 [0.4-0.5])和消费者(OR 0.5 [0.5-0.5])报告比医生报告更少包含可疑药物适应症。
关键数值与推荐
- vigiGrade评分均值:医生0.5,消费者0.4,药师0.4。
- 女性患者比例:药师64.4%、消费者64.8%、医生55.3%。
- 患者平均年龄:药师58.7岁、医生53.5岁、消费者52.6岁。
- 发病时间可计算OR:消费者vs医生1.9 [1.8-1.9],消费者vs药师1.7 [1.6-1.7]。
- 适应症包含OR:药师vs医生0.5 [0.4-0.5],消费者vs医生0.5 [0.5-0.5]。
临床怎么用
- 临床药师可参考消费者报告在发病时间信息上的优势,在用药教育中引导患者记录症状出现时间。
- 药师报告适应症填写较少,提示发药或用药指导环节应主动核实并记录适应症。
- 药物警戒工作中可考虑整合医生、药师和消费者多源报告以提升信息完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adverse drug reactions (ADRs) can be reported by Health Care Professionals (HCPs; e.g., physicians, pharmacists) and non-Health Care Professionals (non-HCPs; e.g., consumers). Previous studies investigating differences between reports from HCPs and non-HCPs rarely considered the completeness of information provided. In addition, they mostly did not distinguish between physicians and pharmacists or were performed years ago. The aim of our study was to analyse and compare the completeness of information provided in reports from physicians, pharmacists and consumers from Germany in a more recent dataset. MATERIALS AND METHODS: We analysed all spontaneous reports from Germany received between 2018 and 2021 in the ADR database EudraVigilance exclusively reported by physicians (n = 69,976), pharmacists (n = 42,396) or consumers (n = 121,144). Demographical parameters of the patients were analysed descriptively. Completeness of reports was evaluated applying an established score (vigiGrade). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression analysis in order to identify report, patient, drug or ADR-specific information provided more often in reports from physicians, pharmacists or consumers. RESULTS: Within the study period the number of reports per year by physicians and pharmacists decreased steadily, while an opposite trend was observed for consumer reports. The proportion of female patients was higher in reports from pharmacists (64.4%) and consumers (64.8%) compared to those from physicians (55.3%). On average, patients in reports from pharmacists (58.7) were older compared to those from physicians (53.5) and consumers (52.6). As an example for the presence of specific information, the time to onset of the ADR could be calculated more often in consumer compared to physician (OR 1.9 [1.8-1.9]) and pharmacist reports (OR 1.7 [1.6-1.7]). In contrast, pharmacist (OR 0.5 [0.4-0.5]) and consumer (OR 0.5 [0.5-0.5]) reports included the indication of the suspected drug less often than physician reports. Physician reports on average (mean = 0.5) were slightly more complete according to the vigiGrade score compared to reports from consumers (mean = 0.4) and pharmacists (mean = 0.4). CONCLUSION: The ADR reports from consumers were comparable with regard to the completeness score with those from physicians and pharmacists underlining their value. Differences in completeness of specific information between the reporter types were found, suggesting that a common reporting of interactions between the three reporters may further improve the completeness of ADR reports. Furthermore, stratified analysis of ADR reports per reporter type may be helpful for certain objectives in scientific research.
引用
- Christ P, Dubrall D, Schmid M, et al. Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers. Drug Saf. 2023. PMID: 37987966. doi:10.1007/s40264-023-01355-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。